Home About Us Our Technology News + Media Investor Relations Contact Us
Company Press Releases Publications


Company Press Releases                                                                               Back

CytoSorbents Sponsors the German Sepsis Society and Sepsis Heroes in Honor of World Sepsis Day

Friday September 7, 2012

MONMOUTH JUNCTION, N.J., Sept. 7, 2012 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care focused company using blood purification to modulate the immune system, reduce severe inflammation, and fight organ failure caused by life-threatening illnesses such as sepsis, announced that it has become a member and sponsor of the Germany Sepsis Society and a sponsor of the Sepsis Heroes Evening, hosted by the Sepsis Alliance, in honor of the first World Sepsis Day on September 13, 2012.

Professor Konrad Reinhart, Chairman of the Board of the Global Sepsis Alliance and Founding President of the German Sepsis Society, stated, "We are happy that such innovative young companies are joining our common effort to find a therapy and solutions for this huge medical and societal problem."

Dr. Phillip Chan, Chief Executive Officer, commented, "We are proud to support these outstanding organizations and to be part of the global effort to create greater awareness of sepsis – a terrible illness that claims the lives of millions of people across the world each year. Often, sepsis is recognized too late because patients don't know what it is and what to look out for, resulting in uncontrolled inflammation, organ failure and death. This is why increasing public awareness is so important. Faster recognition of sepsis and better therapies can save lives. We hope that CytoSorb®, a blood filter approved in the European Union to reduce cytokines that cause excessive inflammation in sepsis, will help tip the scale towards survival in this major unmet medical need."

About the German Sepsis Society

The German Sepsis Society (GSS) is the primary medical society in Germany whose mission is to educate and increase public and professional awareness about sepsis. The organization brings together leaders in sepsis research, diagnostics, treatment, and education in order to also encourage new research, recognize valuable scientific contributions, and foster collaborations to help save lives. A major goal is to support the rapid implementation of effective sepsis diagnostics and therapies into the standard of care treatment for sepsis. Members of the GSS have been heavily involved with SepNet, or the Sepsis Competence Network, a consortium of hospitals and investigators funded for 10 years by the German Federal Ministry of Education to conduct research and clinical trials in sepsis. The GSS also initiated the foundation of the organization, German Sepsis Aid, by people who survived sepsis and their relatives, to provide assistance, information, and networking for those whose lives have been touched by sepsis. For more information, visit www.sepsis-gesellschaft.de/DSG/Englisch

About the Sepsis Alliance™ and Sepsis Heroes Evening

The Sepsis Alliance is a charitable organization run by a team of dedicated laypeople and professionals who share a strong commitment to battling sepsis. The goal is to raise awareness of sepsis through information and educational material so it can be detected and treated early enough that no harm is done. Currently, every year in the United States, over 200,000 people die of sepsis, with many survivors seriously disabled. That is more people in one year than those who die of breast cancer, prostate cancer and AIDS, combined. The Sepsis Heroes Evening is an award reception, being held on World Sepsis Day in New York City, designed to raise awareness of sepsis and to recognize the unique contributions of individuals who have committed their time and energy for the cause. For more information, visit www.sepsisalliance.org

About World Sepsis Day

World Sepsis Day is an initiative of the Global Sepsis Alliance (GSA) and its founding non-profit members: The World Federation of Societies of Intensive and Critical Care Medicine, the World Federation of Pediatric Intensive and Critical Care Societies, the World Federation of Critical Care Nurses, the International Sepsis Forum, and the Sepsis Alliance. The goals of World Sepsis Day are to:

  • Reduce the incidence of sepsis through effective prevention strategies
  • Increase sepsis survival rates for all population groups around the world
  • Provide better access to suitable rehabilitation services for people everywhere
  • Increase awareness and understanding of sepsis among healthcare professionals and the general public
For more information, visit www.world-sepsis-day.org

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in clinical situations where cytokines are elevated. The goal of CytoSorb® is to modulate the immune system by reducing "cytokine storm" in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. CytoSorb® has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies. HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions. CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications, treatment of inflammatory and autoimmune disorders, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and additional CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate and timely financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on March 30, 2012, which is available at http://www.sec.gov.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1910667.

CytoSorbents, Inc
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
Source: CytoSorbents Corporation

Home | Career Opportunities | Contact Us
© 2008 CytoSorbents Incorporated All Rights Reserved